Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Agosto 2023 - 5:05PM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that on August 1,
2023, an authorized sub-committee of the Board of Directors of
Mersana granted inducement awards, consisting of stock options to
purchase an aggregate of 38,775 shares of its common stock and
restricted stock unit awards (RSUs) to acquire an aggregate of
27,655 shares of its common stock, to two new employees whose
employment commenced in July 2023. The awards were granted pursuant
to terms and conditions fixed by the Compensation Committee and as
an inducement material to each new employee entering employment
with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
The option awards have an exercise price of $1.17 per share,
which is equal to the closing price of Mersana’s common stock on
August 1, 2023. Each option has a 10-year term and will vest over a
period of four years, with 25% of the shares vesting on the
one-year anniversary of the commencement of the employee’s
employment and the remainder vesting in equal quarterly
installments over the following three years, subject to the
applicable employee’s continued service with Mersana on each such
vesting date. The options are subject to the terms and conditions
of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and
conditions of a stock option agreement covering each grant.
The RSUs will vest in equal annual installments on the first
four anniversaries of August 15, 2023, subject to the applicable
employee’s continued service with Mersana on each such vesting
date. The RSUs are subject to the terms and conditions of Mersana’s
2022 Inducement Stock Incentive Plan and the terms and conditions
of an RSU agreement covering each grant.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Contact:Jason
Fredette617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Mersana Therapeutics (NASDAQ:MRSN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024